Last reviewed · How we verify
Insulin Biphasic Aspart 30/70
Insulin biphasic aspart 30/70 is a premixed insulin combining 30% rapid-acting aspart and 70% intermediate-acting aspart to provide both immediate and sustained blood glucose control.
Insulin biphasic aspart 30/70 is a premixed insulin combining 30% rapid-acting aspart and 70% intermediate-acting aspart to provide both immediate and sustained blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Biphasic Aspart 30/70 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Premixed insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This combination insulin mimics physiological insulin secretion by providing rapid glucose lowering after meals (via the aspart component) and basal glucose control between meals and overnight (via the intermediate-acting component). The 30/70 ratio allows for convenient once or twice-daily dosing in patients with type 1 or type 2 diabetes who require both prandial and basal insulin coverage.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study (PHASE4)
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (PHASE4)
- Comparison of Two Biphasic Insulin Regimens (NA)
- A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Biphasic Aspart 30/70 CI brief — competitive landscape report
- Insulin Biphasic Aspart 30/70 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI